Home / Formulary / Tesamorelin

Back to formulary

LORIUM · 5 mg LYOPHILISED VIAL

Third-party tested · COA included with every lot

Metabolic ● In stockPrescription required

Tesamorelin

Name: Tesamorelin
Brand: LORIUM
SKU: tesamorelin
Availability: InStock

GHRH analogue · TESAMORELIN

Tesamorelin is a premium, structurally optimized growth hormone-releasing hormone (GHRH) analogue engineered to stimulate the body's natural, pulsatile secretion of endogenous growth hormone. By selectively activating pituitary pathways, this advanced protocol excels at reducing deep, stubborn visceral fat deposits while optimizing lipid biomarkers and supporting overall metabolic health.

$189 / month · 5 mg

Request through a provider Start intake to prescribe

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. It is dispensed only pursuant to a valid prescription following evaluation by a licensed provider.

Researched effects

Effects observed in the cited literature. Individual results are not guaranteed. Statements have not been evaluated by the FDA.

Visceral Fat Reduction

Studied for significantly reducing deep, stubborn abdominal fat.

Lipid Profile Optimization

Positively influences blood lipid ratios, lowering triglycerides and cholesterol.

Body Composition Balance

Selectively targets deep fat tissue without depleting healthy subcutaneous layers.

Hepatic Cellular Support

Effectively decreases localized liver fat accumulation and markers of inflammation.

Natural Amplification

Promotes the body's natural, pulsed growth hormone release.

Glycemic Equilibrium

Enhances natural growth hormone activity without negatively impacting insulin sensitivity.

Sustained Efficacy

Delivers continuous, dependable body composition benefits with consistent protocol adherence.

Specifications

ClassGHRH analogue

CAS number218949-48-5

Molar mass5135.9 g/mol

Available sizes5 mg, 10 mg

AdministrationPremium once-daily subcutaneous protocol.

CategoryMetabolic

View a sample certificate of analysis →

Clinical references

Falutz, J., et al. (2007). Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV. New England Journal of Medicine, 357(23), 2359–2370.
Stanley, T.L., et al. (2019). Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in People with HIV. The Lancet HIV, 6(12), e821–e830.
Fourman, L.T., et al. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 5(16), e138099.
FDA Label: EGRIFTA (tesamorelin) for injection. Prescribing Information.
LiverTox: Tesamorelin. National Institutes of Health